FRI0167 Comparative cardiovascular safety of abatacept and tumor necrosis factor inhibitors in rheumatoid arthritis patients with and without cardiovascular disease: a population-based cohort study

Background Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease (CVD). Recent studies suggested that treatment of RA with tumor necrosis inhibitors (TNFi) can reduce the risk of cardiovascular events. However, it is unclear how abatacept, a selective costimulation modulator, affects cardiovascular risk among RA patients compared with TNFi. Objectives To evaluate the comparative cardiovascular safety of abatacept versus TNFi in RA patients with and without underlying CVD. Methods We identified RA patients aged ≥18 with ≥2 RA ICD-9 codes (714.xx) separated by ≥7 days but Results After 1:1 PS matching, there were 6,102 patient pairs from Medicare and 6,934 pairs from MarketScan. Among them, patients with baseline CVD were 35.3% in Medicare and 14.0% in MarketScan. Baseline characteristics were well balanced between two treatment groups after matching (standardized mean difference Conclusions In this large multi-database population-based study of RA patients, abatacept treatment was associated with reduced risk of CVD compared to TNFi, especially among older population and patients with prior CVD conditions. Disclosure of Interest None declared